HIV
Immunocore Outlines Strategic Priorities on Kimmtrak and TCR Therapy Pipeline
The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that patients outside of cancer may not accept.
Helocyte Gains Rights to Use City of Hope's CMV Vaccine to Boost CAR T-Cell Therapy Efficacy in HIV
Based on preclinical data, experts believe the cancer center's Triplex cytomegalovirus vaccine can stimulate CMV/HIV-CAR T cells to proliferate in patients.
HIV Gene Therapy Developer Addimmune to Go Public Through SPAC Merger
Addimmune, a company launched from American Gene Technologies' HIV drug development program, plans to trade under the ticker symbol "HIV."
Addimmune will separate from AGT within a year with the goal of quickly raising funds and moving AGT103-T into Phase II trials.